- Previous close:
- Day's range:
- $41.92 - $42.85
- Year's range:
- $36.17 - $58.67
- Net Income per Share:
- Price-to-Earnings ratio:
- 52-week Price Range:
- Average volume:
Company profile for Galapagos NV
Galapagos NV is an integrated biopharmaceutical company that specializes in drug discovery, development and commercialization of treatments for unmet medical needs. The company’s products and pipeline products are focused on the treatment of a number of conditions, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel Crohn’s disease, fistulizing Crohn’s Disease, ankylosing spondylitis, psoriatic arthritis, uveitis, osteoarthritis, inflammation, idiopathic pulmonary fibrosis, cystic fibrosis and osteoarthritis.
Galapagos NV has several collaborations with a number of other pharmaceutical companies, including Gilead Sciences, Inc., AbbVie S.à r.l. and Novartis Pharma AG. Galapagos NV’s development programs are based on a number of different approaches, ranging from small molecule to biologics.
The company has already seen success with some of their products and pipeline products, with their JAK1 inhibitor - filgotinib - being approved by the European Medicines Agency (EMA) for the treatment of rheumatoid arthritis, Crohn’s disease and ulcerative colitis. Their Toledo molecules, including GLPG3970, GLPG4399 and GLPG4876, have also been approved by the European Medicines Agency for the treatment of inflammation.
Other pipeline products of Galapagos include GLPG2737, which is a cystic fibrosis transmembrane conductance regulator in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease, and GLPG0555, a JAK1 inhibitor, which is currently in Phase 1b for the treatment of patients with osteoarthritis.
Galapagos NV was established in 1999 and is headquartered in Mechelen, Belgium. It is listed on the Euronext-Brussels stock exchange and on the Nasdaq Global Select Market. The company has more than 2,000 employees, spread across 14 countries and has research and development facilities in Belgium, France, the Netherlands, U.K. and Romania. The company has achieved a number of milestones in drug development and commercialization, including the launch of its first approved medicine, Ziritaxestat, in 2020 and the commercial launch of Triferic, its first commercial product.
- Stock exchanges:
- 32 1 534 29 00